Industry Leader’s Fireside Chat: Tracing Antibody Engineering’s Evolution Into ADC-Style Oligo Delivery & Charting Where the Field Is Headed Next
9:00 am - Wednesday 9th December 2026
Exploring how priorities have shifted across the ecosystem, from proving modality feasibility to solving delivery, scalability and commercialization challenges, and what this means for the next generation of RNA therapeutics.
- Gain insight into the evolving innovation landscape, including how changing investment priorities, strategic collaborations and platform consolidation are influencing the future direction of oligonucleotide therapeutics and partnership opportunities
- Delving into the scientific, manufacturing and strategic considerations that determine whether innovative delivery technologies successfully translate from platform concepts into approved medicines
